Literature DB >> 1680548

Induction of in vitro differentiation of mouse embryonal carcinoma (F9) cells by inhibitors of topoisomerases.

K Kondo1, K Tsuneizumi, T Watanabe, M Oishi.   

Abstract

To investigate the possible involvement of topoisomerases in embryonal differentiation, we examined the effect of topoisomerase inhibitors on the in vitro differentiation of mouse embryonal carcinoma F9 cells. We found that camptothecin, teniposide (VM-26), or genistein, specific inhibitors of topoisomerases, induced morphological as well as biochemical changes (production of tissue plasminogen activator, synthesis of laminin, and disappearance of stage-specific embryonic antigen 1) specific to F9 cell differentiation. Since these changes were indistinguishable from those observed in F9 differentiation induced by retinoic acid (plus dibutyryl cyclic AMP), it was suggested that inhibition of cellular topoisomerase activities triggered F9 cell differentiation into parietal endoderm-like cells in the same manner as retinoic acid (plus dibutyryl cyclic AMP). Experiments using differentiation-resistant mutant F9 cell lines, however, indicated that the molecular cascade involved in topoisomerase inhibitor-induced differentiation involves different steps from those functioning in the retinoic acid-induced differentiation cascade.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1680548

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  Characterisation of normal and cancer stem cells: one experimental paradigm for two kinds of stem cells.

Authors:  Jean-François Mayol; Corinne Loeuillet; Francis Hérodin; Didier Wion
Journal:  Bioessays       Date:  2009-09       Impact factor: 4.345

2.  Targeted disruption of the mouse topoisomerase I gene by camptothecin selection.

Authors:  S G Morham; K D Kluckman; N Voulomanos; O Smithies
Journal:  Mol Cell Biol       Date:  1996-12       Impact factor: 4.272

3.  Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents.

Authors:  Y Kakeji; B A Teicher
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

Review 4.  Risks and benefits of soy phytoestrogens in cardiovascular diseases, cancer, climacteric symptoms and osteoporosis.

Authors:  C R Sirtori
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

5.  Differentiation-inducing activity of hydroxycamptothecin on cancer stem-like cells derived from hepatocellular carcinoma.

Authors:  Yi Zhang; Wen-Jie Song; Fu-Qin Zhang; Wei-Hui Liu; Ke-Feng Dou
Journal:  Dig Dis Sci       Date:  2011-02-12       Impact factor: 3.199

Review 6.  The multifaceted NF-kB: are there still prospects of its inhibition for clinical intervention in pediatric central nervous system tumors?

Authors:  Mariana Medeiros; Marina Ferreira Candido; Elvis Terci Valera; María Sol Brassesco
Journal:  Cell Mol Life Sci       Date:  2021-07-31       Impact factor: 9.261

7.  Inhibition of growth and induction of differentiation of metastatic melanoma cells in vitro by genistein: chemosensitivity is regulated by cellular p53.

Authors:  S Rauth; J Kichina; A Green
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

Review 8.  Phytoestrogens: epidemiology and a possible role in cancer protection.

Authors:  H Adlercreutz
Journal:  Environ Health Perspect       Date:  1995-10       Impact factor: 9.031

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.